Management of aggressive variants of papillary thyroid cancer.

Ying Ki Lee, Aleix Rovira, Paul V Carroll, Ricard Simo

Journal: Current opinion in otolaryngology & head and neck surgery 2024;32(2):125-133

PMID: 38116795

Abstract

PURPOSE OF REVIEW

The aim of this study was to provide a timely and relevant review of the latest findings and explore appropriate management of aggressive variants of papillary thyroid cancer (AVPTC).

RECENT FINDINGS

In general, AVPTCs tend to exhibit more invasive characteristics, a lack of responsiveness to radioiodine, increased occurrences of regional spreading, distant metastases and higher mortality rates. Meanwhile, each variant showcases unique clinical and molecular profiles.

SUMMARY

Given the elevated risk of recurrence postsurgery, a more aggressive strategy may be necessary when suspected preoperatively, particularly for those presenting with invasive features. Decision on the extent of surgical treatment and adjuvant therapy is individualized and made by experienced clinicians and multidisciplinary teams based on the clinical presentation, presence of aggressive features and molecular profile. Future studies on development of personalized medicine and molecular target therapy may offer tailored treatment options.

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

Address: Department of Otorhinolaryngology - Head and Neck Surgery.; Department of Endocrinology and Thyroid Oncology Unit, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.